It has been 20 years since the original publication of the MOPP program from the National Cancer Institute (Bethesda) (DeVita et al., 1970) . During the succeeding years, we have learned that the regimen can give consistent results around the world and that survival is more determined by clinical prognostic factors, such as stage, symptoms and performance status (Longo et al., 1986) . In addition, more dynamic factors, such as the quantity of mustine delivered in the first three cycles, and the rapidity of tumour regression, predict better results. With these benefits came a variety of toxicity problems related to this regimen. Mustine itself produced nausea/vomiting and phlebitis, which could result in dose modification and delays in treatment because of poor compliance by some patients. Severe myelosuppression may occur with mustine which will result in similar irregularities in the administration of MOPP. The Royal Marsden group modified the MVPP regimen (mustine, vinblastine, procarbazine, prednisone) by the substitution of chlorambucil for mustine (ChIVPP) with the first report in 1977 (McElwain et al., 1977) . The long-term follow-up of this and derivative series confirms an effect which is indistinguishable from MOPP or MVPP in comparable patients (Selby et al., 1990; Druker et al., 1989; McKendrick et al., 1989) . Given these results now, clearly a randomised trial is not required. The BNLI trial confirms the similarity of the chlorambucilcontaining regimen (LOPP) to MOPP. Further, the decreased morbidity of ChlVPP was cofirmed. It is clear from this and other trials that acute toxicity of MOPP or MVPP is not necessary to achieve the benefits in advanced Hodgkin's disease. The issue is not completely at rest, however, since the publication of MOPP alternating with ABVD trials have demonstrated a superiority to MOPP alone (Bonadonna et al., 1986) . In addition, the development of the hybrid regimen, MOPP-ABV, has again 'locked in' the use of mustine since the initial very promising results captured the attention of clinicians (Klimo et al., 1988) . The Cancer and Leukemia Group B (CALGB) trial comparing MOPP to ABVD alone and both to the alternating MOPP-ABVD for 12 months showed a superiority of ABVD alone over MOPP, and comparable results to the alternating regimen, MOPP-ABVD. Differences in full-dose delivery were noted between MOPP and ABVD since the latter did not seem to impair the bone marrow function to the same degree as MOPP (Canellos et al., 1988) . The current Intergroup trial in North America is a randomisation between ABVD alone and the MOPP-ABV hybrid.
Clearly, dose rate is an important factor in the chemotherapy of drug responsive tumours. The ChlVPP or LOPP program offer a high rate of dose intensity given the daily administration of chlorambucil. Whether a dose schedule calculated per m2 body mass and adjusted according to bone marrow tolerance rather than a fixed maximum dose of 10 mg per day would have had better results is speculation. With both LOPP and ChlVPP, the patient is not spared the risk of treatment-induced leukaemia albeit a low risk. No leukaemias have been noted with ABVD alone in the Milan and CALGB trials (Valagussa et al., 1982) . The current directions include the exploration of dose intensification, especially in poor prognosis patients. In the better prognosis patients, clearly LOPP or ChlVPP could be substituted for MOPP or MVPP.
Can all alkylating agent-containing regimens be replaced by alternative programs which might reduce the likelihood of sterility and leukaemogenesis without adding new chronic toxicities? A number of trials have now suggested that equivalent or superior results to MOPP can be achieved with ABVD (Canellos et al., 1988; Santoro et al., 1987; Carde et al., 1990) . The next question -whether ABVD can be improved -remains for future trials.
